Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice

Behavioural Brain Research

Volumn 224, Issue 1, 2011, Pages 155-158

  Telegdy, Gyula ^a   Tanaka, Masaru ^a   Schally, Andrew V ^b,c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Department of Pathology and Medicine   (United States)

Author keywords

Antidepressive; Anxiolytic actions; GH RH antagonist MZ 4 71; Memory correction

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; MZ 4 71; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN FUNCTION; BRAIN VENTRICLE; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FORCED SWIMMING TEST; HORMONE ACTION; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

AMYLOID BETA-PEPTIDES; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; GROWTH HORMONE-RELEASING HORMONE; MALE; MAZE LEARNING; MICE; PEPTIDE FRAGMENTS; SERMORELIN; SWIMMING;

EID: 79959558904     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.05.036     Document Type: Article

References (34)

1. Schally A.V., Steelman S.L., Bowers C.Y. Effect of hypothalamic extracts on release of growth hormone in vitro. Proc Soc Exp Biol Med 1965, 119:208-212.
2. Krulich L., Dhariwal A.P., McCann S.M. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968, 83:783-790.
3. Müller E.E., Locatelli V., Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev 1999, 79:511-607.
4. Frohman L.A., Szabo M. Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors that caused acromegaly. Prog Clin Biol Res 1981, 74:259-271.
5. Havt A., Schally A.V., Halmos G., Varga J.L., Toller G.L., Horvath J.E., et al. The expression of the pituitary GH-RH receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 2005, 102:17424-17429.
6. Schally A.V., Varga J.L., Engel J.B. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008, 33-43.
7. Jaeger L.B., Banks W.A., Varga J., Schally A.V. Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumor. Proc Natl Acad Sci USA 2005, 102:12495-12500.
8. Matsubara S., Sato M., Mizobuchi M., Niimi M., Takahara J. Differential gene expression of growth hormonee (GH) releasing hormone (GRH) and GRH receptor in various rat tissues. Endocrinology 1995, 136:4147-4150.
9. Obál F. Effects of peptides (DSIP, DSIP analogues, VIP, GRF and CCK) on sleep in the rat. Clin Neuropharmacol 1986, 9:459-461.
10. Obál F., Alföldi P., Cady A.B., Johannsen L., Sary G., Kruger M. Growth hormone-releasing factor enhances sleep in rats and rabbits. Am J Physiol 1988, 255:R310-R316.
11. Obál F., Alt J., Taishi P., Gardi J., Kruger M. Sleep in mice with nonfunctional growth hormone-releasing hormone receptors. Am J Physiol Regul Integr Comp Physiol 2003, 284:R131-R139.
12. Banks W.A., Morley J.E., Farr S.A., Price T.O., Ercal N., Vidaurre I., et al. Proc Natl Acad Sci USA 2010, 107:22272-22277. [early edition].
13. Ader R., Weijnen J.A.W.M., Moleman P. Retention of a passive avoidance response as a function of the intensity and duration of electric shock. Psychosom Sci 1972, 26:126-128.
14. Telegdy G., Tanaka M., Schally A.V. Effects of the LHRH antagonist cetrorelix on the brain function in mice. Neuropeptides 2009, 4:229-234.
15. Pellow S., Chopin P., File S., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
16. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
17. Khisti R.T., Chopde C.T., Jain S.P. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 2000, 67:137-143.
18. Chen S., Wright J.W., Barnes C.D. The neurochemical and behavioral effects of beta-amyloid peptide (25-35). Brain Res 1996, 720:54-60.
19. Yamaguchi Y., Kawashima Y. Effects of amyloid-B(25-35) on passive avoidance, radial-maze and choline acethyltransferase activity in the rat. Eur J Pharmacol 2001, 412:265-272.
20. Stepanichev M.Y., Moiseeva Y.V., Lazareva N.A., Onufriev M.V., Gulyaeva N.Y. Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long term memory in rats. Brain Res Bull 2003, 61:197-205.
21. Roesler R., Luft T., Oliveira S.H.S., Farias C.B., Almeida V.R., Quevedo J., et al. Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus. Neuropharmacology 2006, 51:350-357.
22. Zarandi M., Horvath J.E., Halmos G., Pinski J., Nagy A., Groot K., et al. Synthesis,and biological activity of highly potent antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci USA 1994, 91:1298-12302.
23. Kovacs M., Zarándi M., Halmos G., Groot K., Schally A.V. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanism of action. Endocrinology 1996, 137:5364-5369.
24. Kovacs M., Kineman R.D., Schally A.V., Zarándi M., Groot K., Frohman L.A. Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly. Endocrinology 1997, 138:4536-4542.
25. Aleman A., Verhaar H.J., De Haan E.H., De Vries W.R., Samson M.M., Drent M.L., et al. Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab 1999, 84:471-475.
26. Kelijman M. Age-related alteration of the growth hormone/insulin-like growth factor-1 axis. J Am Geriatr Soc 1991, 39:295-307.
27. Martin F.C., Yeo A.L., Somsken P.H. Growth hormone secretion in elderly: aging and somatopause. Baillieres Clin Endocrinol Metab 1997, 28:223-250.
28. Sonsken P. Growth hormone and somatopause. Growth Horm IGF Res 1999, 9:1-2.
29. Obermayr R.P., Mayerhofer L., Knechtelsdorfer M., Mersich N., Huber E.R., Geyer G., et al. The age-related down regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male reversed corsiderably by donezepil, a drug for Alzheimer's disease. Exp Gerontol 2005, 40:157-163.
30. Adamik A., Telegdy G. Involvement of different receptors in pituitary adenylate cyclase activating polypeptide induced open field activity in rats. Neuropeptides 2005, 38:16-20.
31. Telegdy G., Tiricz H., Adamik A. Involvement of neurotransmitters in urocortin-induced passive avoidance learning in mice. Brain Res Bull 2005, 67:242-247.
32. Barabutis N., Schally A.V. Growth hormone-releasing hormone. Extrapituitary effects in physiology and pharmacology. Cell Cycle 2010, 9(20):4110-4116.
33. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000, 36:1224-1228.
34. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., Egger M. Insulin-like growth factor (IGF-1), IGF binding protein-3 and cancer risk: systemic review and meta-regression analysis. Lancet 2000, 363:1346-1353.